Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Rates Of Adverse Events And Outcomes Among Ischemic Stroke Patients Admitted To Thrombectomy Capable Stroke Centers
Cerebrovascular Disease and Interventional Neurology
Cerebrovascular Disease and Interventional Neurology Posters (7:00 AM-5:00 PM)
205
To identify the beneficial e!ects of thrombectomy capable hospitals (TCHs), we compared the rates of in-hospital adverse events and discharge outcomes among ischemic stroke patients admitted to thrombectomy capable and non-thrombectomy capable hospitals in the United States.
NA
We obtained the data from the Nationwide Inpatient Sample from 2012 and 2017. Thrombectomy capable hospitals were identified based on number of thrombectomy procedures performed by hospital per year among ischemic stroke patients. If an hospital performed ten or more thrombectomy procedures, it was labelled as thrombecotomy capable hospital. Analysis was limited to patients (age ≥18 years) discharged with a principal diagnosis of ischemic stroke (International Classification of Disease 433.x1-434.x1 (ICD-9) or I63 (ICD-10). Impact of TCHs admissions on in-hospital outcomes was assessed in a comparative analysis of propensity-matched groups of patients.
We identified a total of 2,826,335 patients with primary ischemic stroke patients. After adjusting for age, gender, race or ethnicity, comorbidities, All Patients Refined Diagnosis Related Groups (APR-DRG)-based disease severity, and hospital teaching status, patients admitted to TCHs were at lower risk of in-hospital adverse events complications: pneumonia (odds ratio [OR], 0.86; 95% confidence interval [CI], 0.80-0.93), urinary tract infection (OR, 0.87; 95% CI, 0.84-0.91)and sepsis (OR, 0.92; 95% CI, 0.84-1.00). Patients admitted to TCH were more likely to receive thrombolysis (OR, 1.29; 95% CI, 1.30-1.36). The mean cost of hospitalization of the patients was significantly higher in patients admitted at TCHs compared with those admitted at non-thrombectomy capable $74765 vs $60530, P < .0001). Patients admitted to TCHs had lower inpatient mortality (OR, 0.82; 95% CI, 0.78-.88) and were more likely to be discharged with none to minimal disability (OR, 1.09; 95% CI, 1.06-1.12).
Compared with non-thrombectomy capable admissions, patients admitted to TCHs are less likely to experience hospital adverse events and more likely to experience better discharge outcomes. 
Authors/Disclosures
Saqib A. Chaudhry, MD
PRESENTER 		Dr. Chaudhry has nothing to disclose.
Ibrahim Laleka No disclosure on file
No disclosure on file
No disclosure on file
Yun Fang No disclosure on file
No disclosure on file
Sairah Bashir, MD, FÂ鶹´«Ã½Ó³»­ Dr. Bashir has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic .
No disclosure on file
Haseeb A. Rahman, MD (Baylor University Medical Center Institute) Dr. Rahman has nothing to disclose.
Pouya Tahsili-Fahadan, MD (Johns Hopkins Medical Institutes) Dr. Tahsili-Fahadan has received publishing royalties from a publication relating to health care.
Ameer Hassan, DO (Valley Baptist Medical Center) Dr. Hassan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medtronic. Dr. Hassan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Stryker. Dr. Hassan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Penumbra. Dr. Hassan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Cerenovus. Dr. Hassan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Viz.ai. Dr. Hassan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genentech. Dr. Hassan has received research support from GE Healthcare.
Laith Altaweel, MD (Inova) No disclosure on file
Hamza I. Maqsood, MD (Dept of Neurology) Dr. Qureshi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AstraZeneca.